Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors

[1]  A. Hagemeijer,et al.  Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. , 2001, Blood.

[2]  M. Pfeilstöcker,et al.  Cross‐validation of prognostic scores in myelodysplastic syndromes on 386 patients from a single institution confirms importance of cytogenetics , 1999, British journal of haematology.

[3]  Keith Wheatley,et al.  Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.

[4]  M. Labopin,et al.  Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS , 1997 .

[5]  P. Hurteloup,et al.  Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). , 1997, Blood.

[6]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[7]  C. Declercq,et al.  Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very‐low‐risk group using standard mortality ratio techniques , 1996, British journal of haematology.

[8]  O. Garson,et al.  A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. , 1996, Blood.

[9]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[10]  R. Storb,et al.  An update on allogeneic marrow transplantation for myelodysplastic syndrome. , 1995, Leukemia & lymphoma.

[11]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[12]  R. Gale,et al.  Allogeneic bone marrow transplantation for leukemia. , 1994, Current opinion in hematology.

[13]  P. Fenaux,et al.  Autologous bone marrow transplantation with marrow purged by mafosfamide in seven patients with myelodysplastic syndromes in transformation (AML-MDS): a pilot study. , 1993, Leukemia.

[14]  A. Duhamel,et al.  Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. , 1993, Leukemia.

[15]  F. Appelbaum,et al.  Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. , 1993, Blood.

[16]  D. Collett,et al.  Modeling Binary Data. , 1993 .

[17]  D. Reece,et al.  Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. , 1992, Bone marrow transplantation.

[18]  C. Haanen,et al.  Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia , 1990, Cancer.

[19]  E. Estey,et al.  Peripheral acute leukemia: high peripheral but low-marrow blast count. , 1989, Blood.

[20]  M. Sanz,et al.  Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.

[21]  G. Mufti,et al.  Prognostic features of chronic myelomonocytic leukaemia: a modified Bournemouth score gives the best prediction of survival , 1988, British journal of haematology.

[22]  R. Larson,et al.  High‐dose cytosine arabinoside in the treatment of preleukemic disorders: A leukemia intergroup study , 1986, American journal of hematology.

[23]  D. Cox,et al.  Analysis of Survival Data. , 1985 .

[24]  D. Machin,et al.  Myelodysplastic syndromes: a scoring system with prognostic significance , 1985, British journal of haematology.

[25]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[26]  K. Foon,et al.  Intensive chemotherapy for acute myelogenous leukemia. , 1981, Annals of internal medicine.

[27]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[28]  J. Vardiman.  Myelodysplastic/myeloproliferative diseases. , 2004, Cancer treatment and research.

[29]  P. Thall,et al.  Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB. , 2000, Blood.

[30]  P. Thall,et al.  Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB , 2000 .

[31]  D. Blaise,et al.  Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients. , 1991, Bone marrow transplantation.